Chemokine–chemokine receptors in cancer immunotherapy

Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interestb

Bibliography

• 1  Zlotnik A: Chemokines and cancer. Int. J. Cancer119,2026–2029 (2006).
  Medline CASGoogle Scholar
• 2  Moser B, Wolf M, Walz A, Loetscher P: Chemokines: multiple levels of leukocyte migration control. Trends Immunol.25,75–84 (2004).
  Medline CASGoogle Scholar
• 3  Le Y, Zhou Y, Iribarren P, Wang J: Chemokines and chemokine receptors: their manifold roles in homeostasis and disease. Cell. Mol. Immunol.1,95–104 (2004).
  Medline CASGoogle Scholar
• 4  Murdoch C, Finn A: Chemokine receptors and their role in inflammation and infectious diseases. Blood95,3032–3043 (2000).
  Medline CASGoogle Scholar
• 5  Allavena P, Sica A, Vecchi A, Locati M, Sozzani S, Mantovani A: The chemokine receptor switch paradigm and dendritic cell migration: its significance in tumor tissues. Immunol. Rev.177,141–149 (2000).
  Medline CASGoogle Scholar
• 6  Dieu MC, Vanbervliet B, Vicari A et al.: Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites. J. Exp. Med.188,373–386 (1998).
  Medline CASGoogle Scholar
• 7  Kim CH, Broxmeyer HE: Chemokines: signal lamps for trafficking of T and B cells for development and effector function. J. Leukoc. Biol.65,6–15 (1999).
  Medline CASGoogle Scholar
• 8  Ebert LM, Schaerli P, Moser B: Chemokine-mediated control of T cell traffic in lymphoid and peripheral tissues. Mol. Immunol.42,799–809 (2005).
  Medline CASGoogle Scholar
• 9  Caux C, Ait-Yahia S, Chemin K et al.: Dendritic cell biology and regulation of dendritic cell trafficking by chemokines. Springer Semin. Immunopathol.22,345–369 (2000).
  Medline CASGoogle Scholar
• 10  McColl SR: Chemokines and dendritic cells: a crucial alliance. Immunol. Cell Biol.80,489–496 (2002).
  Medline CASGoogle Scholar
• 11  Balkwill F: Cancer and the chemokine network. Nat. Rev. Cancer4,540–550 (2004).
  Medline CASGoogle Scholar
• 12  Homey B, Muller A, Zlotnik A: Chemokines: agents for the immunotherapy of cancer? Nat. Rev. Immunol.2,175–184 (2002).
  Medline CASGoogle Scholar
• 13  Meijer J, Ogink J, Kreike B, Nuyten D, de Visser KE, Roos E: The chemokine receptor CXCR6 and its ligand CXCL16 are expressed in carcinomas and inhibit proliferation. Cancer Res.68,4701–4708 (2008).
  Medline CASGoogle Scholar
• 14  Belperio JA, Keane MP, Arenberg DA et al.: CXC chemokines in angiogenesis. J. Leukoc. Biol.68,1–8 (2000).
  Medline CASGoogle Scholar
• 15  Salcedo R, Wasserman K, Young HA et al.: Vascular endothelial growth factor and basic fibroblast growth factor induce expression of CXCR4 on human endothelial cells: in vivo neovascularization induced by stromal-derived factor-1α. Am. J. Pathol.154,1125–1135 (1999).
  Medline CASGoogle Scholar
• 16  Bernardini G, Spinetti G, Ribatti D et al.: I-309 binds to and activates endothelial cell functions and acts as an angiogenic molecule in vivo. Blood96,4039–4045 (2000).
  Medline CASGoogle Scholar
• 17  Salcedo R, Young HA, Ponce ML et al.: Eotaxin (CCL11) induces in vivo angiogenic responses by human CCR3⁺ endothelial cells. J. Immunol.166,7571–7578 (2001).
  Medline CASGoogle Scholar
• 18  Tse KP, Tsang NM, Chen KD et al.: MCP-1 Promoter polymorphism at 2518 is associated with metastasis of nasopharyngeal carcinoma after treatment. Clin. Cancer Res.13,6320–6326 (2007).
  Medline CASGoogle Scholar
• 19  Ghilardi G, Biondi ML, La Torre A, Battaglioli L, Scorza R: Breast cancer progression and host polymorphisms in the chemokine system: role of the macrophage chemoattractant protein-1 (MCP-1) -2518 G allele. Clin. Chem.51,452–455 (2005).
  Medline CASGoogle Scholar
• 20  Azenshtein E, Luboshits G, Shina S et al.: The CC chemokine RANTES in breast carcinoma progression: regulation of expression and potential mechanisms of promalignant activity. Cancer Res.62,1093–1102 (2002).
  Medline CASGoogle Scholar
• 21  Manes S, Mira E, Colomer R et al.: CCR5 expression influences the progression of human breast cancer in a p53-dependent manner. J. Exp. Med.198,1381–1389 (2003).
  Medline CASGoogle Scholar
• 22  Zou W, Machelon V, Coulomb-L’Hermin A et al.: Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. Nat. Med.7,1339–1346 (2001).
  Medline CASGoogle Scholar
• 23  Nahon P, Sutton A, Rufat P et al.: Chemokine system polymorphisms, survival and hepatocellular carcinoma occurrence in patients with hepatitis C virus-related cirrhosis. World J. Gastroenterol.14,713–719 (2008).
  Medline CASGoogle Scholar
• 24  Savage SA, Abnet CC, Mark SD et al.: Variants of the IL8 and IL8RB genes and risk for gastric cardia adenocarcinoma and esophageal squamous cell carcinoma. Cancer Epidemiol. Biomarkers Prev.13,2251–2257 (2004).
  Medline CASGoogle Scholar
• 25  Vairaktaris E, Yapijakis C, Serefoglou Z et al.: The interleukin-8 (-251A/T) polymorphism is associated with increased risk for oral squamous cell carcinoma. Eur. J. Surg. Oncol.33,504–507 (2007).
  Medline CASGoogle Scholar
• 26  Ben Nasr H, Chahed K, Mestiri S, Bouaouina N, Snoussi K, Chouchane L: Association of IL-8 (-251)T/A polymorphism with susceptibility to and aggressiveness of nasopharyngeal carcinoma. Hum. Immunol.68,761–769 (2007).
  Medline CASGoogle Scholar
• 27  Snoussi K, Mahfoudh W, Bouaouina N, Ahmed SB, Helal AN, Chouchane L: Genetic variation in IL-8 associated with increased risk and poor prognosis of breast carcinoma. Hum. Immunol.67,13–21 (2006).▪ Along with [28], two recent papers that report a correlation of CXCL8 polymorphisms and breast cancer.
  Medline CASGoogle Scholar
• 28  Kamali-Sarvestani E, Aliparasti MR, Atefi S: Association of interleukin-8 (IL-8 or CXCL8) -251T/A and CXCR2 +1208C/T gene polymorphisms with breast cancer. Neoplasma54,484–489 (2007).▪ Along with [27], two recent papers that report a correlation of CXCL8 polymorphisms and breast cancer.
  Medline CASGoogle Scholar
• 29  Hassan S, Baccarelli A, Salvucci O, Basik M: Plasma stromal cell-derived factor-1: host derived marker predictive of distant metastasis in breast cancer. Clin. Cancer Res.14,446–454 (2008).
  Medline CASGoogle Scholar
• 30  Coelho A, Calcada C, Catarino R, Pinto D, Fonseca G, Medeiros R: CXCL12 -3´A polymorphism and lung cancer metastases protection: new perspectives in immunotherapy? Cancer Immunol. Immunother.55,639–643 (2006).
  MedlineGoogle Scholar
• 31  Dommange F, Cartron G, Espanel C et al.: CXCL12 polymorphism and malignant cell dissemination/tissue infiltration in acute myeloid leukemia. FASEB J.20,1913–1915 (2006).
  Medline CASGoogle Scholar
• 32  de Oliveira CE, Cavassin GG, Perim Ade L et al.: Stromal cell-derived factor-1 chemokine gene variant in blood donors and chronic myelogenous leukemia patients. J. Clin. Lab. Anal.21,49–54 (2007).
  MedlineGoogle Scholar
• 33  Vairaktaris E, Vylliotis A, Spyridonodou S et al.: A DNA polymorphism of stromal-derived factor-1 is associated with advanced stages of oral cancer. AntiCancer Res.28,271–275 (2008).
  Medline CASGoogle Scholar
• 34  Hirata H, Hinoda Y, Kikuno N et al.: CXCL12 G801A polymorphism is a risk factor for sporadic prostate cancer susceptibility. Clin. Cancer Res.13,5056–5062 (2007).
  Medline CASGoogle Scholar
• 35  de Oliveira Cavassin GG, De Lucca FL, Delgado Andre N et al.: Molecular investigation of the stromal cell-derived factor-1 chemokine in lymphoid leukemia and lymphoma patients from Brazil. Blood Cells Mol. Dis.33,90–93 (2004).
  MedlineGoogle Scholar
• 36  Lowe SW, Cepero E, Evan G: Intrinsic tumour suppression. Nature432,307–315 (2004).
  Medline CASGoogle Scholar
• 37  Soengas MS: Cancer: Ins and outs of tumour control. Nature454,586–587 (2008).▪▪ Outlines and compares three recent papers on tumor senescence pathways and their role in tumor progression.
  Medline CASGoogle Scholar
• 38  Krtolica A, Parrinello S, Lockett S, Desprez PY, Campisi J: Senescent fibroblasts promote epithelial cell growth and tumorigenesis: a link between cancer and aging. Proc. Natl Acad. Sci. USA98,12072–12077 (2001).
  Medline CASGoogle Scholar
• 39  Coppe JP, Kauser K, Campisi J, Beausejour CM: Secretion of vascular endothelial growth factor by primary human fibroblasts at senescence. J. Biol. Chem.281,29568–29574 (2006).
  Medline CASGoogle Scholar
• 40  Xue W, Zender L, Miething C et al.: Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature445,656–660 (2007).
  Medline CASGoogle Scholar
• 41  Acosta JC, O’Loghlen A, Banito A et al.: Chemokine signaling via the CXCR2 receptor reinforces senescence. Cell133,1006–1018 (2008).
  Medline CASGoogle Scholar
• 42  Kuilman T, Michaloglou C, Vredeveld LC et al.: Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network. Cell133,1019–1031 (2008).
  Medline CASGoogle Scholar
• 43  Maxwell PJ, Gallagher R, Seaton A et al.: HIF-1 and NF-κB-mediated upregulation of CXCR1 and CXCR2 expression promotes cell survival in hypoxic prostate cancer cells. Oncogene26,7333–7345 (2007).
  Medline CASGoogle Scholar
• 44  Wislez M, Fujimoto N, Izzo JG et al.: High expression of ligands for chemokine receptor CXCR2 in alveolar epithelial neoplasia induced by oncogenic kras. Cancer Res.66,4198–4207 (2006).
  Medline CASGoogle Scholar
• 45  Wajapeyee N, Serra RW, Zhu X, Mahalingam M, Green MR: Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7. Cell132,363–374 (2008).
  Medline CASGoogle Scholar
• 46  Singh RK, Gutman M, Radinsky R, Bucana CD, Fidler IJ: Expression of interleukin 8 correlates with the metastatic potential of human melanoma cells in nude mice. Cancer Res.54,3242–3247 (1994).
  Medline CASGoogle Scholar
• 47  Cabioglu N, Yazici MS, Arun B et al.: CCR7 and CXCR4 as novel biomarkers predicting axillary lymph node metastasis in T1 breast cancer. Clin. Cancer Res.11,5686–5693 (2005).
  Medline CASGoogle Scholar
• 48  Ding Y, Shimada Y, Maeda M et al.: Association of CC chemokine receptor 7 with lymph node metastasis of esophageal squamous cell carcinoma. Clin. Cancer Res.9,3406–3412 (2003).
  Medline CASGoogle Scholar
• 49  Gunther K, Leier J, Henning G et al.: Prediction of lymph node metastasis in colorectal carcinoma by expressionof chemokine receptor CCR7. Int. J. Cancer116,726–733 (2005).
  MedlineGoogle Scholar
• 50  Mashino K, Sadanaga N, Yamaguchi H et al.: Expression of chemokine receptor CCR7 is associated with lymph node metastasis of gastric carcinoma. Cancer Res.62,2937–2941 (2002).
  Medline CASGoogle Scholar
• 51  Takanami I: Overexpression of CCR7 mRNA in nonsmall cell lung cancer: correlation with lymph node metastasis. Int. J. Cancer105,186–189 (2003).
  Medline CASGoogle Scholar
• 52  Muller A, Homey B, Soto H et al.: Involvement of chemokine receptors in breast cancer metastasis. Nature410,50–56 (2001).
  Medline CASGoogle Scholar
• 53  Wiley HE, Gonzalez EB, Maki W, Wu MT, Hwang ST: Expression of CC chemokine receptor-7 and regional lymph node metastasis of B16 murine melanoma. J. Natl Cancer Inst.93,1638–1643 (2001).
  Medline CASGoogle Scholar
• 54  Balkwill F: The significance of cancer cell expression of the chemokine receptor CXCR4. Semin. Cancer Biol.14,171–179 (2004).▪▪ Highlights the importance of the CXCR4–CXCL12 axis in metastasis.
  Medline CASGoogle Scholar
• 55  Salvucci O, Bouchard A, Baccarelli A et al.: The role of CXCR4 receptor expression in breast cancer: a large tissue microarray study. Breast Cancer Res. Treat.97,275–283 (2006).
  Medline CASGoogle Scholar
• 56  Li YM, Pan Y, Wei Y et al.: Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis. Cancer Cell6,459–469 (2004).
  Medline CASGoogle Scholar
• 57  Kang Y, Siegel PM, Shu W et al.: A multigenic program mediating breast cancer metastasis to bone. Cancer Cell3,537–549 (2003).
  Medline CASGoogle Scholar
• 58  Helbig G, Christopherson KW 2nd, Bhat-Nakshatri P et al.: NF-κB promotes breast cancer cell migration and metastasis by inducing the expression of the chemokine receptor CXCR4. J. Biol. Chem.278,21631–21638 (2003).
  Medline CASGoogle Scholar
• 59  Kang H, Watkins G, Parr C, Douglas-Jones A, Mansel RE, Jiang WG: Stromal cell derived factor-1: its influence on invasiveness and migration of breast cancer cells in vitro, and its association with prognosis and survival in human breast cancer. Breast Cancer Res.7,R402–10 (2005).
  Medline CASGoogle Scholar
• 60  Mendelsohn J, Baselga J: Epidermal growth factor receptor targeting in cancer. Semin. Oncol.33,369–385 (2006).
  Medline CASGoogle Scholar
• 61  Allinen M, Beroukhim R, Cai L et al.: Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell6,17–32 (2004).
  Medline CASGoogle Scholar
• 62  Orimo A, Gupta PB, Sgroi DC et al.: Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell121,335–348 (2005).
  Medline CASGoogle Scholar
• 63  Zagzag D, Krishnamachary B, Yee H et al.: Stromal cell-derived factor-1α and CXCR4 expression in hemangioblastoma and clear cell-renal cell carcinoma: von Hippel-Lindau loss-of-function induces expression of a ligand and its receptor. Cancer Res.65,6178–6188 (2005).
  Medline CASGoogle Scholar
• 64  Polyak K, Hahn WC: Roots and stems: stem cells in cancer. Nat. Med.12,296–300 (2006).
  Medline CASGoogle Scholar
• 65  Schabath H, Runz S, Joumaa S, Altevogt P: CD24 affects CXCR4 function in pre-B lymphocytes and breast carcinoma cells. J. Cell. Sci.119,314–325 (2006).
  Medline CASGoogle Scholar
• 66  Koizumi K, Hojo S, Akashi T, Yasumoto K, Saiki I: Chemokine receptors in cancer metastasis and cancer cell-derived chemokines in host immune response. Cancer Sci.98,1652–1658 (2007).
  Medline CASGoogle Scholar
• 67  Kucia M, Reca R, Miekus K et al.: Trafficking of normal stem cells and metastasis of cancer stem cells involve similar mechanisms: pivotal role of the SDF-1–CXCR4 axis. Stem Cells23,879–894 (2005).
  Medline CASGoogle Scholar
• 68  Vicari AP, Treilleux I, Lebecque S: Regulation of the trafficking of tumour-infiltrating dendritic cells by chemokines. Semin. Cancer Biol.14,161–169 (2004).
  Medline CASGoogle Scholar
• 69  Zou W: Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat. Rev. Cancer5,263–274 (2005).▪ How tumor-induced immunosuppression should be considered in the design of therapeutic strategies.
  Medline CASGoogle Scholar
• 70  Murakami T, Cardones AR, Finkelstein SE et al.: Immune evasion by murine melanoma mediated through CC chemokine receptor-10. J. Exp. Med.198,1337–1347 (2003).
  Medline CASGoogle Scholar
• 71  Simonetti O, Goteri G, Lucarini G et al.: Potential role of CCL27 and CCR10 expression in melanoma progression and immune escape. Eur. J. Cancer42,1181–1187 (2006).
  Medline CASGoogle Scholar
• 72  Kohrgruber N, Groger M, Meraner P et al.: Plasmacytoid dendritic cell recruitment by immobilized CXCR3 ligands. J. Immunol.173,6592–6602 (2004).
  Medline CASGoogle Scholar
• 73  Ogilvie P, Paoletti S, Clark-Lewis I, Uguccioni M: Eotaxin-3 is a natural antagonist for CCR2 and exerts a repulsive effect on human monocytes. Blood102,789–794 (2003).
  Medline CASGoogle Scholar
• 74  Tharp WG, Yadav R, Irimia D et al.: Neutrophil chemorepulsion in defined interleukin-8 gradients in vitro and in vivo. J. Leukoc. Biol.79,539–554 (2006).
  Medline CASGoogle Scholar
• 75  Vianello F, Papeta N, Chen T et al.: Murine B16 melanomas expressing high levels of the chemokine stromal-derived factor-1/CXCL12 induce tumor-specific T cell chemorepulsion and escape from immune control. J. Immunol.176,2902–2914 (2006).
  Medline CASGoogle Scholar
• 76  Lee CH, Kakinuma T, Wang J et al.: Sensitization of B16 tumor cells with a CXCR4 antagonist increases the efficacy of immunotherapy for established lung metastases. Mol. Cancer Ther.5,2592–2599 (2006).
  Medline CASGoogle Scholar
• 77  Pollard JW: Tumour-educated macrophages promote tumour progression and metastasis. Nat. Rev. Cancer4,71–78 (2004).
  Medline CASGoogle Scholar
• 78  Allavena P, Sica A, Solinas G, Porta C, Mantovani A: The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. Crit. Rev. Oncol. Hematol.66,1–9 (2008).
  MedlineGoogle Scholar
• 79  Mantovani A, Schioppa T, Porta C, Allavena P, Sica A: Role of tumor-associated macrophages in tumor progression and invasion. Cancer Metastasis Rev.25,315–322 (2006).
  MedlineGoogle Scholar
• 80  Bingle L, Brown NJ, Lewis CE: The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J. Pathol.196,254–265 (2002).
  Medline CASGoogle Scholar
• 81  Ueno T, Toi M, Saji H et al.: Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer. Clin. Cancer Res.6,3282–3289 (2000).
  Medline CASGoogle Scholar
• 82  Dehqanzada ZA, Storrer CE, Hueman MT et al.: Correlations between serum monocyte chemotactic protein-1 levels, clinical prognostic factors, and HER-2/neu vaccine-related immunity in breast cancer patients. Clin. Cancer Res.12,478–486 (2006).
  Medline CASGoogle Scholar
• 83  Sica A, Saccani A, Bottazzi B et al.: Defective expression of the monocyte chemotactic protein-1 receptor CCR2 in macrophages associated with human ovarian carcinoma. J. Immunol.164,733–738 (2000).
  Medline CASGoogle Scholar
• 84  Wang HY, Wang RF: Regulatory T cells and cancer. Curr. Opin. Immunol.19,217–223 (2007).
  Medline CASGoogle Scholar
• 85  Schabowsky RH, Madireddi S, Sharma R, Yolcu ES, Shirwan H: Targeting CD4⁺CD25⁺FoxP3⁺ regulatory T-cells for the augmentation of cancer immunotherapy. Curr. Opin. Investig. Drugs8,1002–1008 (2007).
  Medline CASGoogle Scholar
• 86  Stewart TJ, Greeneltch KM, Lutsiak ME, Abrams SI: Immunological responses can have both pro- and antitumour effects: implications for immunotherapy. Expert Rev. Mol. Med.9,1–20 (2007).▪▪ How immune responses can influence tumor progression and mechanisms whereby tumors escape recognition and destruction. Includes a brief review on the pros and cons of some preclinical models.
  MedlineGoogle Scholar
• 87  Wang HY, Lee DA, Peng G et al.: Tumor-specific human CD4⁺ regulatory T cells and their ligands: implications for immunotherapy. Immunity20,107–118 (2004).
  Medline CASGoogle Scholar
• 88  Curiel TJ, Coukos G, Zou L et al.: Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med.10,942–949 (2004).
  Medline CASGoogle Scholar
• 89  Ishida T, Ishii T, Inagaki A et al.: Specific recruitment of CC chemokine receptor 4-positive regulatory T cells in Hodgkin lymphoma fosters immune privilege. Cancer Res.66,5716–5722 (2006).
  Medline CASGoogle Scholar
• 90  Miller AM, Lundberg K, Ozenci V et al.: CD4⁺CD25^high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. J. Immunol.177,7398–7405 (2006).
  Medline CASGoogle Scholar
• 91  Jordan JT, Sun W, Hussain SF, DeAngulo G, Prabhu SS, Heimberger AB: Preferential migration of regulatory T cells mediated by glioma-secreted chemokines can be blocked with chemotherapy. Cancer Immunol. Immunother.57,123–131 (2008).
  Medline CASGoogle Scholar
• 92  Mizukami Y, Kono K, Kawaguchi Y et al.: CCL17 and CCL22 chemokines within tumor microenvironment are related to accumulation of Foxp3⁺ regulatory T cells in gastric cancer. Int. J. Cancer122,2286–2293 (2008).
  Medline CASGoogle Scholar
• 93  Ishida T, Ueda R: CCR4 as a novel molecular target for immunotherapy of cancer. Cancer Sci.97,1139–1146 (2006).
  Medline CASGoogle Scholar
• 94  Baumforth KR, Birgersdotter A, Reynolds GM et al.: Expression of the Epstein–Barr virus-encoded Epstein–Barr virus nuclear antigen 1 in Hodgkin’s lymphoma cells mediates up-regulation of CCL20 and the migration of regulatory T cells. Am. J. Pathol.173,195–204 (2008).
  Medline CASGoogle Scholar
• 95  Gabrilovich DI, Bronte V, Chen SH et al.: The terminology issue for myeloid-derived suppressor cells. Cancer Res.67(1),425; author reply 426 (2007).
  Medline CASGoogle Scholar
• 96  Serafini P, Borrello I, Bronte V: Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin. Cancer Biol.16,53–65 (2006).
  Medline CASGoogle Scholar
• 97  Bobe P, Benihoud K, Grandjon D, Opolon P, Pritchard LL, Huchet R: Nitric oxide mediation of active immunosuppression associated with graft-versus-host reaction. Blood94,1028–1037 (1999).
  Medline CASGoogle Scholar
• 98  Makarenkova VP, Bansal V, Matta BM, Perez LA, Ochoa JB: CD11b⁺/Gr-1⁺ myeloid suppressor cells cause T cell dysfunction after traumatic stress. J. Immunol.176,2085–2094 (2006).
  Medline CASGoogle Scholar
• 99  Bronte V, Wang M, Overwijk WW et al.: Apoptotic death of CD8⁺ T lymphocytes after immunization: induction of a suppressive population of Mac-1⁺/Gr-1⁺ cells. J. Immunol.161,5313–5320 (1998).
  Medline CASGoogle Scholar
• 100  Schleifer KW, Mansfield JM: Suppressor macrophages in African trypanosomiasis inhibit T cell proliferative responses by nitric oxide and prostaglandins. J. Immunol.151,5492–5503 (1993).
  Medline CASGoogle Scholar
• 101  Serafini P, De Santo C, Marigo I et al.: Derangement of immune responses by myeloid suppressor cells. Cancer Immunol. Immunother.53,64–72 (2004).
  Medline CASGoogle Scholar
• 102  Yang L, DeBusk LM, Fukuda K et al.: Expansion of myeloid immune suppressor Gr⁺CD11b⁺ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell6,409–421 (2004).
  Medline CASGoogle Scholar
• 103  Talmadge JE: Pathways mediating the expansion and immunosuppressive activity of myeloid-derived suppressor cells and their relevance to cancer therapy. Clin. Cancer Res.13,5243–5248 (2007).▪ Outlines the roles that myeloid-derived suppressor cells can have on suppressing immune responses and highlights their relevance in anticancer therapy design.
  Medline CASGoogle Scholar
• 104  Stewart TJ, Lutsiak ME, Abrams SI: Immune consequences of protracted host-tumor interactions in a transgenic mouse model of mammary carcinoma. Cancer Invest.26,237–249 (2008).
  Medline CASGoogle Scholar
• 105  Almand B, Clark JI, Nikitina E et al.: Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J. Immunol.166,678–689 (2001).
  Medline CASGoogle Scholar
• 106  Schmielau J, Finn OJ: Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of T-cell function in advanced cancer patients. Cancer Res.61,4756–4760 (2001).
  Medline CASGoogle Scholar
• 107  Zea AH, Rodriguez PC, Atkins MB et al.: Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res.65,3044–3048 (2005).
  Medline CASGoogle Scholar
• 108  Filipazzi P, Valenti R, Huber V et al.: Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte–macrophage colony-stimulation factor-based antitumor vaccine. J. Clin. Oncol.25,2546–2553 (2007).
  Medline CASGoogle Scholar
• 109  Ochoa AC, Zea AH, Hernandez C, Rodriguez PC: Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma. Clin. Cancer Res.13,721S–726S (2007).
  Medline CASGoogle Scholar
• 110  Liu Y, Van Ginderachter JA, Brys L, De Baetselier P, Raes G, Geldhof AB: Nitric oxide-independent CTL suppression during tumor progression: association with arginase-producing (M2) myeloid cells. J. Immunol.170,5064–5074 (2003).
  Medline CASGoogle Scholar
• 111  Rodriguez PC, Quiceno DG, Zabaleta J et al.: Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res.64,5839–5849 (2004).
  Medline CASGoogle Scholar
• 112  Apolloni E, Bronte V, Mazzoni A et al.: Immortalized myeloid suppressor cells trigger apoptosis in antigen-activated T lymphocytes. J. Immunol.165,6723–6730 (2000).
  Medline CASGoogle Scholar
• 113  Lin EY, Gouon-Evans V, nguyen AV, Pollard JW: The macrophage growth factor CSF-1 in mammary gland development and tumor progression. J. Mammary Gland Biol. Neoplasia7,147–162 (2002).
  MedlineGoogle Scholar
• 114  Gabrilovich D: Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat. Rev. Immunol.4,941–952 (2004).
  Medline CASGoogle Scholar
• 115  Melani C, Chiodoni C, Forni G, Colombo MP: Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB/c mice suppresses immune reactivity. Blood102,2138–2145 (2003).
  Medline CASGoogle Scholar
• 116  Serafini P, Carbley R, Noonan KA, Tan G, Bronte V, Borrello I: High-dose granulocyte–macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Res.64,6337–6343 (2004).
  Medline CASGoogle Scholar
• 117  Bunt SK, Yang L, Sinha P, Clements VK, Leips J, Ostrand-Rosenberg S: Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression. Cancer Res.67,10019–10026 (2007).
  Medline CASGoogle Scholar
• 118  Sinha P, Clements VK, Fulton AM, Ostrand-Rosenberg S: Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Res.67,4507–4513 (2007).
  Medline CASGoogle Scholar
• 119  Kuschert GS, Coulin F, Power CA et al.: Glycosaminoglycans interact selectively with chemokines and modulate receptor binding and cellular responses. Biochemistry38,12959–12968 (1999).
  Medline CASGoogle Scholar
• 120  Hecht I, Hershkoviz R, Shivtiel S et al.: Heparin-disaccharide affects T cells: inhibition of NF-κB activation, cell migration, and modulation of intracellular signaling. J. Leukoc. Biol.75,1139–1146 (2004).
  Medline CASGoogle Scholar
• 121  Sigrist S, Oberholzer J, Bohbot A et al.: Activation of human macrophages by allogeneic islets preparations: inhibition by AOP-RANTES and heparinoids. Immunology111,416–421 (2004).
  Medline CASGoogle Scholar
• 122  Hochart H, Jenkins PV, Preston RJ, Smith OP, White B, O’Donnell J: Concentration-dependent roles for heparin in modifying lipopolysaccharide-induced activation of mononuclear cells in whole blood. Thromb. Haemost.99,570–575 (2008).
  Medline CASGoogle Scholar
• 123  Mellor P, Harvey JR, Murphy KJ et al.: Modulatory effects of heparin and short-length oligosaccharides of heparin on the metastasis and growth of LMD MDA-MB 231 breast cancer cells in vivo. Br. J. Cancer97,761–768 (2007).▪ Recent report demonstrating the effects of heparin on tumor growth and metastasis.
  Medline CASGoogle Scholar
• 124  Harvey JR, Mellor P, Eldaly H, Lennard TW, Kirby JA, Ali S: Inhibition of CXCR4-mediated breast cancer metastasis: a potential role for heparinoids? Clin. Cancer Res.13,1562–1570 (2007).
  Medline CASGoogle Scholar
• 125  Kakkar AK, Levine MN, Kadziola Z et al.: Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J. Clin. Oncol.22,1944–1948 (2004).
  Medline CASGoogle Scholar
• 126  Veldkamp CT, Peterson FC, Pelzek AJ, Volkman BF: The monomer-dimer equilibrium of stromal cell-derived factor-1 (CXCL 12) is altered by pH, phosphate, sulfate, and heparin. Protein Sci.14,1071–1081 (2005).
  Medline CASGoogle Scholar
• 127  Sutton A, Friand V, Papy-Garcia D et al.: Glycosaminoglycans and their synthetic mimetics inhibit RANTES-induced migration and invasion of human hepatoma cells. Mol. Cancer Ther.6,2948–2958 (2007).
  Medline CASGoogle Scholar
• 128  Proudfoot AE, Fritchley S, Borlat F et al.: The BBXB motif of RANTES is the principal site for heparin binding and controls receptor selectivity. J. Biol. Chem.276,10620–10626 (2001).
  Medline CASGoogle Scholar
• 129  Veillard NR, Braunersreuther V, Arnaud C et al.: Simvastatin modulates chemokine and chemokine receptor expression by geranylgeranyl isoprenoid pathway in human endothelial cells and macrophages. Atherosclerosis188,51–58 (2006).
  Medline CASGoogle Scholar
• 130  Arya M, Ahmed H, Silhi N, Williamson M, Patel HR: Clinical importance and therapeutic implications of the pivotal CXCL12–CXCR4 (chemokine ligand-receptor) interaction in cancer cell migration. Tumour Biol.28,123–131 (2007).
  MedlineGoogle Scholar
• 131  Wang J, Loberg R, Taichman RS: The pivotal role of CXCL12 (SDF-1)/CXCR4 axis in bone metastasis. Cancer Metastasis Rev.25,573–587 (2006).
  Medline CASGoogle Scholar
• 132  Liang Z, Yoon Y, Votaw J, Goodman MM, Williams L, Shim H: Silencing of CXCR4 blocks breast cancer metastasis. Cancer Res.65,967–971 (2005).
  Medline CASGoogle Scholar
• 133  Rubin JB, Kung AL, Klein RS et al.: A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors. Proc. Natl Acad. Sci. USA100,13513–13518 (2003).
  Medline CASGoogle Scholar
• 134  De Falco V, Guarino V, Avilla E et al.: Biological role and potential therapeutic targeting of the chemokine receptor CXCR4 in undifferentiated thyroid cancer. Cancer Res.67,11821–11829 (2007).
  Medline CASGoogle Scholar
• 135  Lapteva N, Yang AG, Sanders DE, Strube RW, Chen SY: CXCR4 knockdown by small interfering RNA abrogates breast tumor growth in vivo. Cancer Gene Ther.12,84–89 (2005).
  Medline CASGoogle Scholar
• 136  Liang Z, Wu T, Lou H et al.: Inhibition of breast cancer metastasis by selective synthetic polypeptide against CXCR4. Cancer Res.64,4302–4308 (2004).
  Medline CASGoogle Scholar
• 137  Yoon Y, Liang Z, Zhang X et al.: CXC chemokine receptor-4 antagonist blocks both growth of primary tumor and metastasis of head and neck cancer in xenograft mouse models. Cancer Res.67,7518–7524 (2007).
  Medline CASGoogle Scholar
• 138  Khan A, Greenman J, Archibald SJ: Small molecule CXCR4 chemokine receptor antagonists: developing drug candidates. Curr. Med. Chem.14,2257–2277 (2007).
  Medline CASGoogle Scholar
• 139  Robinson SC, Scott KA, Wilson JL, Thompson RG, Proudfoot AE, Balkwill FR: A chemokine receptor antagonist inhibits experimental breast tumor growth. Cancer Res.63,8360–8365 (2003).
  Medline CASGoogle Scholar
• 140  Zhan W, Liang Z, Zhu A et al.: Discovery of small molecule CXCR4 antagonists. J. Med. Chem.50,5655–5664 (2007).
  Medline CASGoogle Scholar
• 141  Kim SY, Lee CH, Midura BV et al.: Inhibition of the CXCR4/CXCL12 chemokine pathway reduces the development of murine pulmonary metastases. Clin. Exp. Metastasis25,201–211 (2008).
  Medline CASGoogle Scholar
• 142  Ruffini PA, Morandi P, Cabioglu N, Altundag K, Cristofanilli M: Manipulating the chemokine–chemokine receptor network to treat cancer. Cancer109,2392–2404 (2007).
  Medline CASGoogle Scholar
• 143  Murphy A, Westwood JA, Teng MW, Moeller M, Darcy PK, Kershaw MH: Gene modification strategies to induce tumor immunity. Immunity22,403–414 (2005).
  Medline CASGoogle Scholar
• 144  Fushimi T, Kojima A, Moore MA, Crystal RG: Macrophage inflammatory protein 3a transgene attracts dendritic cells to established murine tumors and suppresses tumor growth. J. Clin. Invest.105,1383–1393 (2000).
  Medline CASGoogle Scholar
• 145  Fushimi T, O’Connor TP, Crystal RG: Adenoviral gene transfer of stromal cell-derived factor-1 to murine tumors induces the accumulation of dendritic cells and suppresses tumor growth. Cancer Res.66,3513–3522 (2006).
  Medline CASGoogle Scholar
• 146  Furumoto K, Soares L, Engleman EG, Merad M: Induction of potent antitumor immunity by in situ targeting of intratumoral DCs. J. Clin. Invest.113,774–783 (2004).
  Medline CASGoogle Scholar
• 147  Hillinger S, Yang SC, Zhu L et al.: EBV-induced molecule 1 ligand chemokine (ELC/CCL19) promotes IFN-γ-dependent antitumor responses in a lung cancer model. J. Immunol.171,6457–6465 (2003).
  Medline CASGoogle Scholar
• 148  Westermann J, nguyen-Hoai T, Baldenhofer G et al.: CCL19 (ELC) as an adjuvant for DNA vaccination: induction of a Th1-type T-cell response and enhancement of antitumor immunity. Cancer Gene Ther.14,523–532 (2007).
  Medline CASGoogle Scholar
• 149  Howard OM, Dong HF, Shirakawa AK, Oppenheim JJ: LEC induces chemotaxis and adhesion by interacting with CCR1 and CCR8. Blood96,840–845 (2000).
  Medline CASGoogle Scholar
• 150  Giovarelli M, Cappello P, Forni G et al.: Tumor rejection and immune memory elicited by locally released LEC chemokine are associated with an impressive recruitment of APCs, lymphocytes, and granulocytes. J. Immunol.164,3200–3206. (2000).
  Medline CASGoogle Scholar
• 151  Guiducci C, Di Carlo E, Parenza M et al.: Intralesional injection of adenovirus encoding CC chemokine ligand 16 inhibits mammary tumor growth and prevents metastatic-induced death after surgical removal of the treated primary tumor. J. Immunol.172,4026–4036 (2004).
  Medline CASGoogle Scholar
• 152  Vicari AP, Ait-Yahia S, Chemin K, Mueller A, Zlotnik A, Caux C: Antitumor effects of the mouse chemokine 6chemokine/SLC through angiostatic and immunological mechanisms. J. Immunol.165,1992–2000 (2000).
  Medline CASGoogle Scholar
• 153  Sharma S, Stolina M, Luo J et al.: Secondary lymphoid tissue chemokine mediates T cell-dependent antitumor responses in vivo. J. Immunol.164,4558–4563 (2000).
  Medline CASGoogle Scholar
• 154  Sharma S, Stolina M, Zhu L et al.: Secondary lymphoid organ chemokine reduces pulmonary tumor burden in spontaneous murine bronchoalveolar cell carcinoma. Cancer Res.61,6406–6412 (2001).
  Medline CASGoogle Scholar
• 155  Yang SC, Batra RK, Hillinger S et al.: Intrapulmonary administration of CCL21 gene-modified dendritic cells reduces tumor burden in spontaneous murine bronchoalveolar cell carcinoma. Cancer Res.66,3205–3213 (2006).
  Medline CASGoogle Scholar
• 156  Yang SC, Hillinger S, Riedl K et al.: Intratumoral administration of dendritic cells overexpressing CCL21 generates systemic antitumor responses and confers tumor immunity. Clin. Cancer Res.10,2891–2901 (2004).
  Medline CASGoogle Scholar
• 157  Liu Y, Huang H, Saxena A, Xiang J: Intratumoral coinjection of two adenoviral vectors expressing functional interleukin-18 and inducible protein-10, respectively, synergizes to facilitate regression of established tumors. Cancer Gene Ther.9,533–542 (2002).
  Medline CASGoogle Scholar
• 158  Narvaiza I, Mazzolini G, Barajas M et al.: Intratumoral coinjection of two adenoviruses, one encoding the chemokine IFN-γ-inducible protein-10 and another encoding IL-12, results in marked antitumoral synergy. J. Immunol.164,3112–3122 (2000).
  Medline CASGoogle Scholar
• 159  Palmer K, Hitt M, Emtage PC, Gyorffy S, Gauldie J: Combined CXC chemokine and interleukin-12 gene transfer enhances antitumor immunity. Gene Ther.8,282–290 (2001).
  Medline CASGoogle Scholar
• 160  Loetscher M, Gerber B, Loetscher P et al.: Chemokine receptor specific for IP10 and mig: structure, function, and expression in activated T-lymphocytes. J. Exp. Med.184,963–969 (1996).
  Medline CASGoogle Scholar
• 161  Taub DD, Lloyd AR, Conlon K et al.: Recombinant human interferon-inducible protein 10 is a chemoattractant for human monocytes and T lymphocytes and promotes T cell adhesion to endothelial cells. J. Exp. Med.177,1809–1814 (1993).
  Medline CASGoogle Scholar
• 162  Angiolillo AL, Sgadari C, Taub DD et al.: Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo. J. Exp. Med.182,155–162 (1995).
  Medline CASGoogle Scholar
• 163  Guiducci C, Vicari AP, Sangaletti S, Trinchieri G, Colombo MP: Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection. Cancer Res.65,3437–3446 (2005).
  Medline CASGoogle Scholar
• 164  Huang H, Xiang J: Synergistic effect of lymphotactin and interferon γ-inducible protein-10 transgene expression in T-cell localization and adoptive T-cell therapy of tumors. Int. J. Cancer109,817–825 (2004).
  Medline CASGoogle Scholar
• 165  Emtage PC, Wan Y, Hitt M et al.: Adenoviral vectors expressing lymphotactin and interleukin 2 or lymphotactin and interleukin 12 synergize to facilitate tumor regression in murine breast cancer models. Hum. Gene Ther.10,697–709 (1999).
  Medline CASGoogle Scholar
• 166  Del Vecchio M, Bajetta E, Canova S et al.: Interleukin-12: biological properties and clinical application. Clin. Cancer Res.13,4677–4685 (2007).
  Medline CASGoogle Scholar
• 167  Rousseau RF, Haight AE, Hirschmann-Jax C et al.: Local and systemic effects of an allogeneic tumor cell vaccine combining transgenic human lymphotactin with interleukin-2 in patients with advanced or refractory neuroblastoma. Blood101,1718–1726 (2003).
  Medline CASGoogle Scholar
• 168  Russell HV, Strother D, Mei Z et al.: Phase I trial of vaccination with autologous neuroblastoma tumor cells genetically modified to secrete IL-2 and lymphotactin. J. Immunother.30,227–233 (2007).
  Medline CASGoogle Scholar
• 169  Kershaw MH, Wang G, Westwood JA et al.: Redirecting migration of T cells to chemokine secreted from tumors by genetic modification with CXCR2. Hum. Gene Ther.13,1971–1980 (2002).
  Medline CASGoogle Scholar